CRISPR names Andrew J. Silver as CFO as Raju Prasad resigns
CRISPR Therapeutics (CRSP) appointed Andrew J. Silver as CFO effective October 19, 2026, replacing Raju Prasad, who resigned to pursue external opportunities. Silver has been with the company since 2018 and previously served as SVP, Finance.
How this was made
The 30-second read
Why it matters
The appointment is a standard corporate governance update with limited price impact.
Market read
Executive change news for a mid‑cap biotech; modest relevance for traders.
What to watch
The departing CFO's departure reason and the new CFO's track record at Ernst & Young may influence longer‑term confidence.
Background
CRISPR Therapeutics filed an 8‑K announcing the CFO transition.
Ticker impact
Andrew J. Silver appointed CFO of CRISPR Therapeutics, replacing Raju Prasad who resigned.
likely neutral as investors weigh the leadership change.
No material guidance or strategic shift was disclosed; the market typically reacts modestly to CFO appointments.
Market effects
Minimal effect on the broader biotech sector; CFO changes are company‑specific.
U.S. investors may adjust positions, but no regional ripple expected.
Limited global relevance beyond CRISPR's shareholders.
Counterpoint
If the new CFO brings aggressive cost‑control, the stock could see upside despite neutral expectations.
Key entities
- personAndrew J. Silver
New Chief Financial Officer of CRISPR Therapeutics
- personRaju Prasad
Outgoing CFO of CRISPR Therapeutics
